Abstract：Objective: To compare the efficacy of entecavir and adefovir dipivoxil for the treatment of hepatitis B-related cirrhosis associated with hepatogenous diabetes.Methods: 60 patients with hepatitis B-related cirrhosis associated with hepatogenous diabetes were randomly assigned to the entecavir group or adefovir dipivoxil group each including 30 patients.Entecavir group received entecavir tablets 0.5 mg qd,and adefovir dipivoxil group received adefovir dipivoxil tablets 10 mg qd.Patients in both groups were given diabetic diet,blood glucose control with insulin,and liver protection.The two groups were compared for liver function indicators,Child-Pugh score,HBV DNA load,hepatic fibrosis indicators(PCⅢ,Ⅳ-C,LN,HA),and glucose metabolic indicators(FBG and HbA1c)following 48 weeks of treatment.Results: Compared to adefovir dipivoxil group,there were significant improvements in liver function indicators,Child-Pugh score,HBV DNA load,hepatic fibrosis indicators,and glucose metabolic indicators following treatment in entecavir group(P<0.05).Conclusion: Entecavir could effectively suppress HBV replication,and improve liver function,Child-Pugh score,HBV DNA load,hepatic fibrosis indicators,and glucose metabolic indicators for patients with hepatitis B-related cirrhosis associated with hepatogenous diabetes,with the efficacy superior over adefovir dipivoxil.
杨军, 魏敏, 李艳芳. 两种核苷(酸)类药物治疗乙型肝炎肝硬化伴肝源性糖尿病的疗效比较[J]. 河北医学, 2017, 23(3): 442-445.
YANG Jun, et al. Comparison of Efficacy of Two Nucleosides for the Treatment of Hepatitis B-Related Cirrhosis Associated with Hepatogenous Diabetes. HeBei Med, 2017, 23(3): 442-445.
[1] 张萍,杨雁.肝源性糖尿病的研究现况[J].华中科技大学学报(医学版),2010,39(1):136~139. [2] Porepa L,Ray JG,Sanchez-Romeu P,et al.Newly diagnosed diabetes mellitus as a risk factor for serious liver disease[J].CMAJ,2010,182(11):E526~531. [3] 苟卫,王燕玲,周永,等.恩替卡韦治疗乙型肝炎肝硬化伴肝源性糖尿病患者对肝纤维化指标的影响[J].临床肝胆病杂志,2014,30(12):1330~1333. [4] 骆抗先,陈金军,李平.乙型肝炎基础和临床[M].第4版.北京:人民卫生出版社,2012.605~607. [5] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].胃肠病学,2011,16(6):351~366. [6] 科技部十二五重大专项联合课题组.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].中华消化杂志,2014,34(2):77~84. [7] Petit JM,Hamza S,Rollot F,et al.Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis[J].Acta Diabetol,2014,51(3):455~460. [8] 罗德兰,颜琼,杨丹,等.高血糖与糖尿病肝纤维化[J].中国中西医结合消化杂志,2014,22(7):412~415.
2017, Vol. 23 
冀公网安备13080202000677号